POS0865 THE CORRELATION BETWEEN FOUR ADHERENCE MEASUREMENTS METHODS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING METHOTREXATE

Background Methotrexate (MTX) is the cornerstone in pharmacological treatment of rheumatoid arthritis (RA) patients. However, medication adherence to MTX not ideal, which might lead suboptimal outcomes. Consequently instruments assess non-adherence are warranted detect and intervene on non-adherence. To date there no consensus best method determine MTX. Objectives The aim this study was correlation between compliance measured with MEMS (gold standard) versus pill count, MTX-polyglutamate (PG) concentration Compliance Questionnaire Rheumatology (CQR) patients established RA. Second, correlations these methods Disease Activity Scores 28 joints (DAS28) were examined. Methods Adult RA treated included. Multivariable linear logistic regression used, taking assessed as dependent variable MTX-PG concentrations, CQR, independent variables, DAS28 score each 4 measurements methods. Comedication, age use corticosteroids NSAIDs included covariates analysis. Results 190 consecutive Median follow-up time 4.9 months (IQR 3.6 – 6.2). Pill count correlated (linear regression, β =.690, p = <.001), whereas concentrations CQR not. Logistic only confirmed dichotomized (β 5.64, =.001). No other found. Between outcomes scores seen. Conclusion Taking MEMS, nor DAS28. can be used estimate therapy, when feasible. Table 1. multiple imputation analyses (pooled). Dependent variable: 95% confidence interval forβ Lower bound Upper IV 0.690 <0.001* 0.377 1.004 0.000 0.341 0.001 0.035 0.399 -0.046 0.116 0.748 -0.003 0.004 -0.180 0.544 -0.761 0.402 0.262 0.118 0.087 -0.017 0.253 Missing data imputed 50 imputations. MEMS: Medication Event Monitoring System, LN transformed; CQR: Rheumatology; IV: variable; beta: unstandardized coefficient; * Significance at 0.05. For following final model: age, centre, amount medication, corticosteroid-use, or COX-2 inhibitors. DAS28, were: way living status (e.g., alone, a partner), educational level, biological-use, comedication baseline REFERENCES: NIL. Acknowledgements: Disclosure Interests None Declared.